Anticipated Launch of Novel Molecules Will Drive Growth of the Neurodegenerative Disease Market in Forecast Period

Friday 21 October 2011, Amsterdam

Anticipated Launch of Novel Molecules Will Drive Growth of the Neurodegenerative Disease Market in Forecast Period

The global neurodegenerative therapeutics market is valued as $16,828m in 2010, and grew from $11,055m in 2002 with a Compound Annual Growth Rate (CAGR) of 5.4%. An increase in the geriatric population globally, along with an increase in life expectancy, is expected to increase the disease population of neurodegenerative diseases. The product pipeline for neurodegenerative disease therapeutics is promising, with many novel molecules with disease modifying characteristics at various stages of clinical development, and these are expected to fulfill the unmet needs in the Neurodegenerative Disease Market. The product pipeline for multiple sclerosis has many orally administered novel molecules, while the Alzheimer’s disease therapeutic pipeline has novel molecules such as bapineuzumab, solanezumab, and BMS-708163, which target the underlying causes of the disease and thus may offer significant benefits to patients. The product pipeline also has promising molecules for rare disorders such as Huntington’s disease and amyotrophic lateral sclerosis and had shown better safety and efficacy profiles in clinical development. Although in the coming years the market will witness the patent expiries of major drugs, the rapid uptake of new molecules will stabilize the market decline and the market is expected to grow with a CAGR of 5.9% from 2010 to 2017 to reach $25,118m in 2017.


Multiple Scleroses and Alzheimer's Disease Therapeutics Markets Contribute Major Share of Global Neurodegenerative Disease Market in 2010

The global neurodegenerative therapeutics market for six indications, including Alzheimer’s disease, Multiple sclerosis, Parkinson’s disease, Diabetic neuropathy, Huntington’s disease and Amyotrophic lateral sclerosis (ALS) therapeutic was valued at $16,828m in 2010.  The multiple sclerosis and Alzheimer’s disease therapeutics markets were the major revenue generators in the neurodegenerative therapeutics market in 2010. The market for multiple sclerosis accounts for 44% of the total market, with some major revenue generator drugs such as Avonex (Interferon beta-1a), Rebif (interferon beta-1a), Tysabri (natalizumab) and Copaxone (glatiramer acetate). The multiple sclerosis market accounted for $7,375m in 2010. The Alzheimer’s disease therapeutics market was the second major market with a 29% share in the Neurodegenerative Disease Market which contributed $4.9 billion due to some major drugs such as Aricept (donepezil hydrochloride), Namenda (memantine HCL), Exelon (rivastigmine tartrate), and others. The Parkinson’s disease therapeutics market stands third with a share of 17%, followed by diabetic neuropathy, with a share of 8% in global neurodegenerative therapeutics market. The orphan disorders Huntington’s disease and ALS contribute 1% each to the global neurodegenerative therapeutics market in 2010.


Strong Product Pipeline for the Neurodegenerative Disease Ensures the Growth of Neurodegenerative Disease Market in Future

More than 800 research and development (R&D) programs are being carried out for neurodegenerative disease.

Out of the total R&D molecules, 43% of the molecules are meant for the treatment of Alzheimer’s disease, and are at various stages of clinical development. These include many molecules focusing on the underlying cause of the disease and targeting secretase, acts by binding to amyloid beta (Abeta) inhibits amyloid precursor protein (APP) and many other novel mechanisms.  The molecules for the treatment of multiple sclerosis, constitutes almost 18% of the total R&D molecules. These include some molecules that are meant for oral administration. Gilenya from Novartis was approved by the FDA in 2010 and many other molecules are in line to receive approval from the FDA. Some 21% of the total pipeline molecules are at various stages of development for the treatment of Parkinson’s disease, and for a few molecules such as Rotigotine from UCB group, NDAs have been filed. Molecules for Huntington’s disease and diabetic neuropathy constitute 5% each of the total R&D pipeline The product pipeline for the orphan diseases such as ALS is also promising, with almost 8% of the total molecules being developed for the treatment of ALS. Some of promising molecules for HD are AMR-101, HD-02 and Huntexil, which is in Phase III of clinical development. Expected launch of these molecules in forecast period will drive Huntington’s disease market.


About this new market study:
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. The report provides an in-depth analysis of the major neurodegenerative disease including Alzheimer’s disease, Multiple sclerosis, Parkinson disease, Diabetic neuropathy and also orphan neurodegenerative diseases such as Huntington’s disease and Amyotrophic lateral sclerosis. The report also provides information on the share of generics in Neurodegenerative Disease Markets and examines the global treatment usage patterns for neurodegenerative diseases. In addition, the geographical distribution of neurodegenerative diseases and therapeutics market across the US, the top five countries of Europe and in Japan. The report also includes insights into the neurodegenerative disease therapeutics research and development (R&D) product pipeline and explores the competitive landscape, including major players in the Neurodegenerative Disease Market. Finally, the report also includes analysis of the Mergers and Acquisitions (M&As) and licensing agreements that have taken place in the Neurodegenerative Disease Market